MET and non-small cell lung carcinoma: Togashi and others used CRISPR/Cas9 system to knock out the exon of MET 14 in HEK293 cell line, MET phosphorylation raised, protein expression increased, cell proliferation was reinforced, and cell sensitivity to Crizotinib was improved (Togashi et al., 2015), demonstrating that targeted therapy for MET exon 14 deleted non-small cell lung cancer holds promise.